JP2009530613A5 - - Google Patents

Download PDF

Info

Publication number
JP2009530613A5
JP2009530613A5 JP2009500495A JP2009500495A JP2009530613A5 JP 2009530613 A5 JP2009530613 A5 JP 2009530613A5 JP 2009500495 A JP2009500495 A JP 2009500495A JP 2009500495 A JP2009500495 A JP 2009500495A JP 2009530613 A5 JP2009530613 A5 JP 2009530613A5
Authority
JP
Japan
Prior art keywords
subject
gelsolin
level
composition
multiple sclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009500495A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009530613A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/006581 external-priority patent/WO2007106577A2/en
Publication of JP2009530613A publication Critical patent/JP2009530613A/ja
Publication of JP2009530613A5 publication Critical patent/JP2009530613A5/ja
Pending legal-status Critical Current

Links

JP2009500495A 2006-03-15 2007-03-14 多発性硬化症を治療するため、および神経疾患を診断するための、ゲルゾリンの使用 Pending JP2009530613A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78250906P 2006-03-15 2006-03-15
PCT/US2007/006581 WO2007106577A2 (en) 2006-03-15 2007-03-14 Gelsolin in the treatment and diagnosis of neurological disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011271607A Division JP6203995B2 (ja) 2006-03-15 2011-12-12 多発性硬化症を治療するため、および神経疾患を診断するための、ゲルゾリンの使用

Publications (2)

Publication Number Publication Date
JP2009530613A JP2009530613A (ja) 2009-08-27
JP2009530613A5 true JP2009530613A5 (enExample) 2010-05-06

Family

ID=38510104

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009500495A Pending JP2009530613A (ja) 2006-03-15 2007-03-14 多発性硬化症を治療するため、および神経疾患を診断するための、ゲルゾリンの使用
JP2011271607A Active JP6203995B2 (ja) 2006-03-15 2011-12-12 多発性硬化症を治療するため、および神経疾患を診断するための、ゲルゾリンの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011271607A Active JP6203995B2 (ja) 2006-03-15 2011-12-12 多発性硬化症を治療するため、および神経疾患を診断するための、ゲルゾリンの使用

Country Status (11)

Country Link
US (2) US8440622B2 (enExample)
EP (1) EP2002258B1 (enExample)
JP (2) JP2009530613A (enExample)
CN (1) CN101460843B (enExample)
CA (1) CA2680333C (enExample)
DK (1) DK2002258T3 (enExample)
ES (1) ES2651619T3 (enExample)
HU (1) HUE035980T2 (enExample)
PL (1) PL2002258T3 (enExample)
PT (1) PT2002258T (enExample)
WO (1) WO2007106577A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9408891B2 (en) * 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
ES2848385T3 (es) * 2003-11-12 2021-08-09 Univ Pennsylvania Métodos de uso de gelsolina para tratar o prevenir septicemia bacteriana
CA2607686C (en) 2004-05-12 2014-11-04 Thomas P. Stossel Use of gelsolin to treat infections
JP4348631B2 (ja) * 2005-03-29 2009-10-21 セイコーエプソン株式会社 半導体素子の製造方法
AU2007227613A1 (en) 2006-03-15 2007-09-27 The Brigham And Women's Hospital, Inc. Use of gelsolin to diagnose and treat inflammatory diseases
JP5778425B2 (ja) 2008-01-25 2015-09-16 ザ ジェネラル ホスピタル コーポレイション 腎不全におけるゲルソリンの診断的および治療的使用
WO2009124226A2 (en) * 2008-04-03 2009-10-08 The Trustees Of The University Of Pennsylvania Gelsolin uses in neurological disorders
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
DE102010026500A1 (de) * 2010-07-07 2012-01-12 Arthrogen Gmbh Verfahren zur Herstellung von autologen Proteinen
EP3279668B1 (en) * 2010-12-16 2019-05-15 National Institute of Advanced Industrial Science and Technology Method for enrichment and separation of spinal fluid glycoprotein, method for searching for marker for central nervous system diseases which utilizes the aforementioned method, and marker for central nervous system diseases
KR101416954B1 (ko) 2012-09-12 2014-07-16 한양대학교 산학협력단 조혈세포 분화 유도 방법
WO2015137738A1 (ko) * 2014-03-11 2015-09-17 한양대학교 산학협력단 혈액질환 진단
FR3036188B1 (fr) * 2015-05-12 2019-06-07 Biomerieux Prediction du risque de developper, pour des patients admis en service de reanimation, une infection disseminee
JP6947449B2 (ja) * 2016-06-29 2021-10-13 学校法人自治医科大学 バイオマーカー、診断用組成物、及び診断用キット
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
HRP20250396T1 (hr) 2016-08-31 2025-05-23 Mapi Pharma Ltd. Depo sustavi koji sadrže glatiramer acetat
AU2018242998B2 (en) 2017-03-26 2023-11-02 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
WO2019173258A1 (en) * 2018-03-05 2019-09-12 Academia Sinica Methods and kits for diagnosing and/or treating peripheral neuropathy
WO2020263484A1 (en) * 2019-06-28 2020-12-30 Mayo Foundation For Medical Education And Research Methods and materials for treating neuromyelitis optica spectrum diseases
EP4204818A1 (en) * 2020-09-23 2023-07-05 Bioaegis Therapeutics Inc. Compositions and methods for identifying and treating microparticle-associated diseases and conditions

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US627353A (en) * 1899-06-20 Cis robinson
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
CA2016227A1 (en) 1989-05-18 1990-11-18 Xandra O. Breakefield Genetic diagnosis of torsion dystonia
US5464817A (en) 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
ATE171625T1 (de) 1990-04-11 1998-10-15 Brigham & Womens Hospital Therapeutische verwendung von actin-bindenden verbindungen
JPH05501503A (ja) 1990-05-04 1993-03-25 バイオジェン，インコーポレイテッド 多量体ゲルゾリン融合構築物
US5571511A (en) 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
JP3507486B2 (ja) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
US5360350A (en) 1991-08-23 1994-11-01 The Whitaker Corporation Sealant compositions and sealed electrical connectors
US5691160A (en) 1992-08-14 1997-11-25 Biogen, Inc. Effects of actin filaments of fibrin clot structure and lysis
US5593964A (en) 1993-10-07 1997-01-14 The George Washington University Medical Center Method of treating septic shock by preventing actin polymerization
JP3914272B2 (ja) 1993-12-28 2007-05-16 中外製薬株式会社 アドゼベリンをコードする遺伝子
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US5846743A (en) 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US5804427A (en) 1995-05-19 1998-09-08 University Of Massachusetts Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
US5925529A (en) 1995-06-07 1999-07-20 The Regents Of The University Of California Method for discovery of peptide agonists
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US5750353A (en) 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
JP2001505219A (ja) 1996-12-04 2001-04-17 ザ・ビクトリア・ユニバーシティ・オブ・マンチェスター 創傷の治癒および線維症の治療
EP1003501B9 (en) 1997-04-02 2005-06-08 The Brigham And Women's Hospital, Inc. Use of an agent for lowering the risk of cardiovascular disease
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US6409599B1 (en) 1999-07-19 2002-06-25 Ham On Rye Technologies, Inc. Interactive virtual reality performance theater entertainment system
JP2004532386A (ja) 2001-01-26 2004-10-21 オックスフォード グリコサイエンシズ（ユーケー）リミテッド 多発性硬化症を診断および治療するためのタンパク質、遺伝子、およびこれらの使用
EP1249244A1 (en) 2001-04-13 2002-10-16 Universiteit Gent Therapeutic compositions for the treatment of a disease modulated by the G-actin / F-actin equilibrium, especially a respiratory tract disease
EP2266595A3 (en) 2002-02-06 2011-07-06 Regenerx Biopharmaceuticals, Inc. Treatment of infections and other disorders
WO2003088811A2 (en) 2002-04-16 2003-10-30 The Brigham And Women's Hospital, Inc. Gelsolin as a prognostic marker of artherosclerotic diseases
AU2003253014A1 (en) 2002-06-21 2004-01-06 Innogenetics N.V. Method for the diagnosis and differential diagnosis of neurological diseases
AU2003289716A1 (en) 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
EP1627076A4 (en) 2003-03-14 2008-07-02 Ppd Biomarker Discovery Scienc BIOLOGICAL MARKERS FOR THE DIAGNOSIS OF RHEUMATOID ARTHRITIS
ES2848385T3 (es) 2003-11-12 2021-08-09 Univ Pennsylvania Métodos de uso de gelsolina para tratar o prevenir septicemia bacteriana
US9408891B2 (en) 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
CA2607686C (en) 2004-05-12 2014-11-04 Thomas P. Stossel Use of gelsolin to treat infections
EP1753455A2 (en) * 2004-06-04 2007-02-21 Genentech, Inc. Method for treating multiple sclerosis
WO2007041245A2 (en) * 2005-09-29 2007-04-12 Biogen Idec Ma Inc. Biomarkers for multiple sclerosis and methods of use thereof
AU2007227613A1 (en) 2006-03-15 2007-09-27 The Brigham And Women's Hospital, Inc. Use of gelsolin to diagnose and treat inflammatory diseases
JP5778425B2 (ja) 2008-01-25 2015-09-16 ザ ジェネラル ホスピタル コーポレイション 腎不全におけるゲルソリンの診断的および治療的使用

Similar Documents

Publication Publication Date Title
JP2009530613A5 (enExample)
JP2009530612A5 (enExample)
Durham CGRP-receptor antagonists-a fresh approach to migraine therapy?
Ryan et al. Effects of heated humidification and topical steroids on compliance, nasal symptoms, and quality of life in patients with obstructive sleep apnea syndrome using nasal continuous positive airway pressure
JP2020176155A5 (enExample)
WO2007092427A3 (en) Treatment of endotoxemia using endotoxin neutralizing agents
Ying et al. Water treadmill training attenuates blood-spinal cord barrier disruption in rats by promoting angiogenesis and inhibiting matrix metalloproteinase-2/9 expression following spinal cord injury
Berger et al. Neurosurgical ablative procedures for intractable cancer pain
Nakamura et al. Efficacy of probenecid for a patient with juvenile dermatomyositis complicated with calcinosis.
DELAKAS et al. Extracorporeal shockwave lithotripsy for urinary calculi in autosomal dominant polycystic kidney disease
Semple et al. Early gelatinase activity is not a determinant of long-term recovery after traumatic brain injury in the immature mouse
JP2014500327A5 (enExample)
BR0012408A (pt) Métodos para induzir ou aumentar a migração celular, para reduzir ou inibir a migração celular, para induzir ou aumentar a cura de ferimento em um paciente, e para regular a expressão de pelo menos um gene de uma célula, e, uso de um agonista de fator de tecido
Arnaoutakis et al. Serum levels of neuron-specific ubiquitin carboxyl-terminal esterase-L1 predict brain injury in a canine model of hypothermic circulatory arrest
Dudzik et al. The Impact of Sauna on Health
WO2005030265A3 (en) Optical imaging of endometriosis
Na et al. Evolving therapeutic strategies in the inflammatory bowel disease
JP2008508253A5 (enExample)
Mukkannavar Effect of combination therapy [TENS and ultrasound] and ischemic compression in the treatment of active myofascial trigger points
Li et al. Effect of combination of parenteral edaravone and nimodipine on ischemic cerebral injury following cerebral hemorrhage
Manole et al. Preclinical neurorehabilitation with environmental enrichment confers cognitive and histological benefits in a model of pediatric asphyxial cardiac arrest
Saxena et al. Modulators and Poststroke Behavioral Changes
Sateia et al. 0395 Clinical Practice Guideline For The Pharmacologic Treatment Of Chronic Insomnia In Adults: An American Academy Of Sleep Medicine Clinical Practice Guideline
MX2020011341A (es) Una composicion para el tratamiento de una o mas enfermedades relacionadas con los estrogenos.
Boumlah et al. Uric Acid Administration Attenuates Severe Protracted Relapsing Remitting Experimental Autoimmune Encephalomyelitis in Dark Agouti rats